The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2414 (INSIGHT): A randomized phase III trial incorporating pathologic complete response in participants with early-stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting.
 
Jeremy Cetnar
Employment - Oregon Health & Science University (OHSU) (I)
 
Yingqi Zhao
No Relationships to Disclose
 
Raymond Osarogiagbon
Employment - Baptist Memorial Healthcare Corporation/Baptist Cancer Center
Stock and Other Ownership Interests - BridgeBio Pharma; Gilead Sciences; Immunocore; Lilly; Pfizer; Revolution Medicines
Honoraria - AstraZeneca; MEDIAN Technologies
Consulting or Advisory Role - American Cancer Society; AstraZeneca; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Triptych Health Partners
Patents, Royalties, Other Intellectual Property - 2 US and 1 China patents for lymph node specimen collection kit and method of pathologic evaluation.
Travel, Accommodations, Expenses - American Cancer Society; MEDIAN Technologies
 
Bruna Pellini
Employment - H. Lee Moffitt Cancer Center and Research Institute; Miami Cancer Institute
Honoraria - AstraZeneca; Bayer; Foundation Medicine; Gilead Sciences; Lilly; Merck; Regeneron
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BlossomHill; Boehringer Ingelheim; Bristol-Myers Squibb/Roche; Caris Life Sciences; Caris MPI; Catalyst Pharmaceuticals; Foundation Medicine; Gilead Sciences; Illumina; Lilly; Merus; oncohost; Regeneron; Thermo Fisher Scientific
Research Funding - Bristol Myers Squibb Foundation (Inst); Bristol-Myers Squibb; Merck (Inst); Moffitt Cancer Center (Inst); National Cancer Institute (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; Gilead Sciences; MSD; Regeneron
 
Theresa Boyle
Employment - Moffitt Cancer Center
Honoraria - Revolution Medicines
Consulting or Advisory Role - Abbvie
Patents, Royalties, Other Intellectual Property - Development of a transcriptomic assay for trial prescreening
 
Humberto Trejo Bittar
No Relationships to Disclose
 
Sanja Dacic
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech
 
Paul Hesketh
Consulting or Advisory Role - UpToDate
 
Krishna Gunturu
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Daiichi Sankyo/Lilly; Merck
 
Ming-Hui Hsieh
No Relationships to Disclose
 
Joseph Unger
Consulting or Advisory Role - AstraZeneca; Loxo/Lilly
Research Funding - Arnold Ventures
 
Dwight Owen
Honoraria - Chugai Pharma; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Nuvalent, Inc. (Inst); Onc.AI (Inst); Palobiofarma (Inst); Pfizer (Inst); Tango Therapeutics (Inst); Tubulis GmbH (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Genentech; Janssen Biotech
 
Jennifer Suga
No Relationships to Disclose
 
Daphna Gelblum
No Relationships to Disclose
 
Fred Hirsch
Leadership - CHOSA Oncology; Henlius
Consulting or Advisory Role - Agilent; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech; Merck; Nectin Therapeutics; Novartis; Novocure; Oncocyte; Sanofi/Regeneron
Research Funding - Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
Expert Testimony - Gerson Lehrman Group
 
Jhanelle Gray
Honoraria - Amgen; AstraZeneca; CatalYM; Coherus Biosciences; Daiichi Sankyo, Inc; Flatiron Health; Genentech; Gilead Sciences; GO2 for Lung Cancer; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Pfizer; Regeneron; Takeda; Zai Lab
Consulting or Advisory Role - Amgen; AstraZeneca; Catalym; Coherus Biosciences; Daiichi Sankyo/UCB Japan; Flatiron Health; Genentech; Gilead Sciences; GO2 for Lung Cancer; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Lilly; Merck; Novartis; Pfizer; Regeneron; Takeda; Zai Lab
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Catalym (Inst); Genentech (Inst); Gilead Services (Inst); GO2 for Lung Cancer (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie